Table 5.
Effect of curcumin on the completed clinical trials.
| Sl No. | Clincal Trial Identifier | Trial Title | No. of Participants | Inclusion Criteria | Year of Completion | Primary Outcome | Clinical Trial No. | Follow-Up Period |
|---|---|---|---|---|---|---|---|---|
| 1. | NCT03085680 | Curcumin and Function in Older Adults | 21 | Aged above 65 years with a CRP level greater than 1.0 mg/dL | 2020 | To examine the effects of dietary supplementation with curcumin on changes in physical function, walking speed (400 m walk test) and grip strength | 2 | 90 days |
| 2. | NCT03211104 | Comparison of Duration of Treatment Interruption with or without Curcumin During the Off Treatment Periods in Patients with Prostate Cancer Undergoing Intermittent Androgen Deprivation Therapy | 107 | Patients with localized prostate cancer or metastatic prostate cancer at the time of diagnosis who received intermittent androgen deprivation therapy (IAD) | 2015 | To determine whether the period from the first interruption of the androgen deprivation therapy to the time when androgen deprivation therapy needs to be retreated differs between the curcumin group and placebo group | NA | 180 days |
| 3. | NCT04012424 | The Effect of Premedication with Curcumin on Post-endodontic Pain | 44 | Patients in the age range of 20–55 years with acute pulpitis | 2020 | Change in postoperative pain after a single endodontic visit | N/A | 2 days |
| 4. | NCT04870060 | Ability of Curcumin to Decrease Cytokines Involved in Mucositis in the Autologous Transplant | 40 | Patients aged 18 years and above with a creatinine clearance greater than 50 mL/min and a serum bilirubin level greater than 2 mg/dl | 2015 | To calculate TNFa, IL-1, IL-6, IL-8, IL-17, TGF-B, IFN-gamma and E2 levels | 2 | 28 days |
| 5. | NCT01543386 | Effects of Curcumin on Vascular Reactivity | 21 | 50- to 70-year-old smokers | 2012 | Changes in brachial flow-mediated dilatation | 2 | 5 days |
| 6. | NCT03568513 | Effect of Curcumin on Gut Microbiota in IBS | 4 | Patients aged 10 to 18 years with diarrhoea-predominant IBS | 2020 | Alterations in gut microbiota | N/A | 56 days |
| 7 | NCT03864783 | The Effect of Curcumin on Liver Fat Content in Obese Subjects | 39 | BMI and haemoglobin greater than 30.0 kg/m2 and 7.5 mmol/L, respectively |
2020 | Curcumin’s effect on steatosis | N/A | 42 days |
| 8. | NCT04044417 | Curcumin-Simvastatin-EDTA in the Treatment of Periodontitis | 30 | Patients aged 25 to 50 years suffering from at least a single posterior 2–3 wall periodontal pocket of depth | 2018 | Reduction in probing depth | 4 | 180 days |
| 9. | NCT04032132 | Curcumin Paste as an Adjunctive Therapy in Periodontitis | 24 | Patients aged 25 to 45 years with at least a single posterior 2–3 wall periodontal defect of pocket depth | 2018 | Evaluate the influence of curcumin paste on the clinical outcomes of the surgical treatment | 4 | 180 days |
| 10. | NCT03746158 | Interindividual Variation in Excretion of Curcumin | 8 | 18–30-year-old healthy adults. | 2019 | Determine the concentration of curcumin and its metabolites in human fecal samples | N/A | 28 days |
| 11. | NCT01179256 | Effect of Supplemental Oral Curcumin in Patients with Atopic Asthma | 16 | Patients aged 18–60 years on low- or medium-dose inhaled corticosteroids | 2010 | Improvement in post-bronchodilator FEV1 | N/A | N/A |
| 12. | NCT01246973 | Oral Curcumin for Radiation Dermatitis in Breast Cancer Patients | 686 | Females aged 21–120 years | 2015 | To measure the Mean Radiation Dermatitis Severity Score | 2 | 42 days |
| 13. | NCT04119752 | Effect of Curcumin on Microvascular Response and Tissue Oxygenation in Older People | 28 | Aged 60– 85 years with two or more risk factors for cardiovascular disease | 2020 | Changes in microvascular reactivity and tissue oxygen saturation. | N/A | 120 min |
| 14. | NCT02255370 | Curcumin Associated with Thiopurin in the Prevention of Post-op Recurrence in Crohn Disease (POPCUR) | 61 | Patients aged 18 years and older with Crohn’s disease | 2018 | Rutgeerts endoscopic score | 3 | 180 days |
| 15. | NCT02298985 | Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients | 38 | Patients aged 18–60 years with schizophrenia and a SANS greater than 30 points | 2017 | Positive and Negative Symptoms Scale (PANSS) | 4 | 180 days |
| 16. | NCT01383161 | 18-Month Study of Memory Effects of Curcumin | 46 | Aged 50–90 years with a modified Ischemic score of less than 4 | 2017 | Change from the baseline to 18 months on the Brief Visual Memory Test-Revised | 2 | 540 days |
| 17. | NCT01333917 | Curcumin Biomarkers | 40 | Healthy volunteers aged 40–80 years | 2013 | To understand the changes in gene expression, the ribonucleic acid (RNA) level and apoptosis | 1 | 30 days |
| 18. | NCT01875822 | Open-label Study of Curcumin C-3 Complex in Schizophrenia | 17 | Patients aged 18–65 years with DSMIV schizophrenia and a SANS greater than 30 | 2012 | To understand the change from the baseline negative symptoms: alogia, anhedonia, social withdrawal and lack of motivation | 2 | 112 days |
| 19. | NCT02978339 | A Study Evaluating the Safety and Efficacy of Curcumin in Patients with Primary Sclerosing Cholangitis (PSC) | 15 | Diagnosed with primary sclerosing cholangitis with alkaline phosphatase >1.5× | 2019 | Change in Serum Alkaline Phosphatase (SAP) | 2 | 84 days |
| 20. | NCT04208334 | The Effect of Curcumin for Treatment of Cancer Anorexia-Cachexia Syndrome in Patients with Stage III-IV of Head and Neck Cancer (CurChexia) | 20 | Patients with stage 3–4 head and neck cancer | 2021 | To measure muscle mass | 2 | 60 days |
| 21. | NCT01925287 | Oral Bioavailability of Curcumin from Micronized Powder and Liquid Micelles in Healthy Young Women and Men | 23 | Healthy volunteers with a normal range blood chemistry value | 2013 | To determine total curcumin, demethoxycurcumin and bisdemethoxycurcumin after deconjugation with beta-glucuronidase | 1 | 24 h |
| 22. | NCT02104752 | Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia | 39 | Volunteers diagnosed with DSM-5 schizophrenia with a corrected vision of at least 20/30 | 2017 | Measurement and treatment research to improve cognition in schizophrenia | 1 | 56 days |
| 23. | NCT02369549 | Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease | 518 | Patients with an eGFR between 15 and 60 mL/min/1.73 m2 with a minimum of 300 mg of protein in urine or with a albumin/creatinine ratio of at least 300 mg | 2020 | Change in albuminuria and the Estimated Glomerular Filtration Rate (eGFR) | 3 | 180 days |
| 24. | NCT02439385 | Avastin/FOLFIRI in Combination with Curcumin in Colorectal Cancer Patients with Unresectable Metastasis | 50 | Colon or rectal cancer patients aged above 19 years with an ASA score of less than 3 | 2019 | To evaluate progression-free survival in colorectal cancer patients | 2 | 730 days |
| 25. | NCT02474953 | A Study to Compare the Pharmacokinetic Profile of a Proprietary Curcumin Formulation to a Comparator Curcumin Product (15PCHB) | 12 | Volunteers aged 18–45 years with a BMI that is 18–29.9 kg/m2(±1 kg/m2) | 2015 | To measure the maximum concentration of curcumin and time until the max concentration of curcumin | 1 | 48 h |
| 26. | NCT04421716 | Testing the Bioavailability of Phytonutrients, Curcumin and Ursolic Acid | 18 | Men aged 18 years or older | 2021 | To evaluate the number, frequency, duration and relation of toxicity events to CURC and UA, the peak serum concentration, the half-life and the time taken to reach the maximum concentration | 1 | 14 days |
| 27. | NCT04258501 | Exploratory Study of Efficacy on Selected Natural Extracts Reducing Post Prandial Blood Glucose Response | 72 | 20–50-year-old healthy individuals with a normal BMI | 2012 | Change in post-prandial blood glucose | NA | 2 h |
| 28. | NCT01035580 | Trial on Safety and Pharmacokinetics of Intravaginal Curcumin | 13 | Volunteers aged 18–45 years currently using a birth control method | 2012 | To reach the maximum selected dose or maximum tolerated dose of intravaginal curcumin without a dose-limiting toxicity | 1 | 14 days |
| 29. | NCT01403545 | Evaluation of Liposomal Curcumin in Healthy Volunteers | 50 | Volunteers in the age group of 18–45 years with a BMI between 18–27 kg/m2 | 2012 | Safety and tolerability of increasing doses of intravenous liposomal curcumin | 1 | 7 days |
| 30. | NCT01225094 | Curcumin to Prevent Complications After Elective Abdominal Aortic Aneurysm (AAA) Repair | 606 | Volunteers aged 18 years or above who have undergone the repair of AAA | 2016 | To measure urine IL-18, NT-ProBNP, hsCRP and serum creatinine | 2 | N/A |
| 31. | NCT01160302 | Curcumin Biomarker Trial in Head and Neck Cancer | 33 | Volunteers aged between 18–90 years willing to undergo tumor biopsies | 2016 | Change in tissue biomarkers and pharmacokinetics of microgranular curcumin | 1 | 28 days |
| 32. | NCT01917890 | Radiosensitizing and Radioprotective Effects of Curcumin in Prostate Cancer | 40 | Aged between 50–80 years with relapsed or treated basal skin cancer and no severe hypertension | 2013 | Biochemical or clinical progression-free survival | N/A | 365 days |
| 33. | NCT00895167 | The Effects of Oral Curcumin on Heme Oxygenase-1 (HO-1) in Healthy Male Subjects (CUMAHS) | 12 | Aged between 18–45 years with a BMI between 18 and 28 kg/m2 | 2009 | The maximal HO-1 mRNA expression and HO-1 protein level in PBMCs | 1 | 48 h |
| 34. | NCT03542240 | Effects of Curcumin Supplementation on Gut Barrier Function in Patients with Metabolic Syndrome | 15 | Waist Circumference—Female: ≥ 88 cm, Male: ≥ 102 cm B. Blood Pressure: ≥ 130/85 mm/Hg. Impaired fasting glucose or HbA1c fasting glucose ≥ 100 mg/dL or HgA1c ≥ 5.7 D. HDL-C—Females: < 50 mg/dL, Males: < 40 mg/dL E. Triglycerides ≥ 150 mg/dL | 2020 | Change in intestinal permeability and intestinal barrier function | N/A | 365 days |
| 35. | NCT00927485 | Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP) | 44 | 21–85 years with FAP (with an intact colon or who have had surgery) | 2016 | To determine the number of polyps and the size of polyps | 5 years | |
| 36. | NCT01042938 | Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients | 35 | Females aged 21 years or above with a diagnosis of non-inflammatory breast adenocarcinoma | 2011 | Severity of dermatitis in the radiation treatment site in breast cancer patients | 2 | 49 days |
| 37. | NCT01490996 | Combining Curcumin with FOLFOX Chemotherapy in Patients with Inoperable Colorectal Cancer (CUFOX) | 41 | 18 years or above, diagnosed with metastatic colorectal cancer and with an ECOG status of 0 or 1 | 2017 | Completion of dose escalation over two cycles of therapy | 2 | 365 days |
| 38. | NCT01975363 | Pilot Study of Curcumin for Women with Obesity and High Risk for Breast Cancer | 29 | Females with an increased risk of breast cancer and a BMI between 25–40 | 2016 | Determine the adherence, tolerability and safety of two doses of nanoemulsion curcumin | N/A | 90 days |
| 39. | NCT01859858 | Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients with Solid Tumors | 23 | Aged above 19 years with adequate bone marrow, renal and hepatic function and an ECOG status of 0 or 1 | 2016 | Maximum tolerated dose, pharmacokinetics of irinotecan and SN-38 | 1 | 28 days |
| 40. | NCT04103788 | Evaluation of Increased Absorption of a Curcumin Emulsion (CurQ+) in Healthy Volunteers | 10 | Aged between 21 and 75 years | 2018 | Comparative effect of differing serum sample preparation methodologies on curcumin absorption levels | N/A | 6 h |
| 41. | NCT01925547 | Micellar Curcumin and Metabolic Syndrome Biomarkers | 42 | Total cholesterol > 5.2 mmol/L, LDL cholesterol > 3.4 mmol/L, Triglyceride > 2.26 mmol/L, CRP > 2 mg/L | 2014 | To measure the serum CRP level | 2 | 42 days |
| 42. | NCT01330810 | Curcumin Pharmacokinetics | 12 | Aged between 16 and 65 years with a BMI in the range of 18–30 kg/m2 | 2012 | To measure the AUC, Cmax, Tmax, Ke, T1/2, Vd and bioequivalence of tissue curcumin concentration | 1 | 48 h |
| 43. | NCT02908152 | Curcumin Supplement in Nonalcoholic Fatty Liver Patients | 50 | Patients diagnosed with type 2 diabetes with a CAP score greater than 263 | 2017 | To measure hepatic steatosis | 2 | 72 days |
| 44. | NCT01201694 | Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L) | 28 | Patients aged 13 or older with an ECOG status of 3 or better and normal organ and marrow function | 2014 | To measure the Maximum Tolerated Dose (MTD) of surface-controlled water-dispersible curcumin | 1 | 28 days |
| 45. | NCT04028739 | Theracurmin vs. Curcumin Bioavailability Study | 24 | Healthy adults aged 19–60 years with a BMI of 18–30 kg/m2 | 2019 | To compare the bioavailability of curcumin in healthy adults | NA | 12 h |
| 46. | NCT03795792 | Oral Curcumin Administration to Remit Metabolic Syndrome | 105 | Men and women aged 20–55 years old with metabolic syndrome according to the ATP III criteria | 2019 | Remission of metabolic syndrome (≤2 components according to the ATP III criteria) | NA | 3 months |
| 47. | NCT00528151 | A Randomized, Double-blind, Placebo-controlled Trial of Curcumin in Leber’s Hereditary Optic Neuropathy (LHON) | 70 | Aged 8 years or older with Leber’s hereditary optic neuropathy | 2007 | Visual outcome | 3 | 1 year |
| 48 | NCT00889161 | Curcumin in Pediatric Inflammatory Bowel Disease | 11 | 8–18-year-old patients with IBD who have been on IBD medication for 3 months | 2010 | To determine the tolerability of curcumin in pediatric patients with inflammatory bowel disease | 1 | 9 weeks |
| 49 | NCT01514266 | Effect of Curcumin on Lung Inflammation | 57 | ≥45-year-old patients with COPD and a stable clinical course | 2010 | Change in sputum dysplasia | NA | 3 months |
| 50 | NCT00779493 | Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial (CuTIBS) | 17 | ≥18-year-old patients who conform to the Rome III criteria | 2009 | The primary outcome will be defined as at least a 50% reduction in the irritable bowel severity score (IBSS) | 4 | 6 months |
| 51 | NCT03329781 | Modulation of Endotoxaemia Via Curcumin Intake in Healthy Overweight Adults (ENDOCUR) | 16 | 18–45-year-old healthy individuals with a BMI ≥ 25 kg/m2 | 2018 | Level of endotoxin in plasma | NA | 21 days |
| 52 | NCT00094445 | Trial of Curcumin in Advanced Pancreatic Cancer | 50 | ≥45-year--old patients with unresectable adenocarcinoma of the pancreas | 2014 | 6-month participant survival | 2 | 6 months |
| 53 | NCT01750359 | Efficacy and Safety Curcumin in Depression | 40 | 20–60-year-old patients with a major depressive disorder | 2011 | Change in Hamilton Depression Rating Scale and Montgomery–Asberg Depression Rating Scale | 4 | 6 weeks |
| 54 | NCT00181662 | Pharmacokinetics of Curcumin in Healthy Volunteers | 6 | ≥45year-old healthy female individuals | 2007 | Curcumin pharmacology | NA | NA |
| 55 | NCT03598205 | Curcumin and Intravitreal Dexamethasone in Diabetic Macular Edema (DIABEC) | 72 | 18–90-year-old patients with significant diabetic macular edema and a central retinal thickness of >300 microns | 2019 | Mean difference in central retinal thickness from baseline to 6 months | NA | 6 months |
| 56 | NCT00641147 | Curcumin in Treating Patients with Familial Adenomatous Polyposis | 44 | 18–85-year-old patients with familial adenomatous polyposis | 2016 | The average number of polyps in the placebo arm at the end of the study is compared to the average in the curcumin arm | 2 | 12 months |
| 57 | NCT04385979 | Curcumin and Nanocurcumin in Oral Aphthous Ulcer | 48 | Patients with minor and recurrent aphthous ulcers with 48 h | 2020 | Wound size and pain score | NA | 1 week |
| 58 | NCT01320436 | Curcumin + aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative Colitis | 50 | 18–70-year-old patients with confirmed diagnosis of ulcerative colitis on a stable dose of ulcerative colitis medication | 2014 | The percentage of patients who achieve clinical remission compared between the two study arms | 3 | 4 weeks |
| 59 | NCT03072992 | “Curcumin” in Combination with Chemotherapy in Advanced Breast Cancer | 150 | 18–75-year-old female patients diagnosed with breast carcinoma and adequate organ function | 2019 | Objective response rate, assessed with the Modified Response Evaluation Criteria in Solid Tumours (RECIST) | 2 | 24 weeks |
| 60 | NCT00113841 | Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients with Multiple Myeloma | 42 | Patients with multiple myeloma and adequate organ function | 2009 | Percent change of NF-kB protein expression in peripheral blood mononuclear cells | NA | 4 weeks |
| 61 | NCT01909037 | Exploratory non comparative Study to Evaluate the Efficacy of Highly Bioavailable Curcumin (Flexofytol) in Patients with Knee Osteoarthritis | 22 | 45–80-year-old patients with osteoarthritis and a symptomatic knee for more than 6 months who can avoid using analgesics during the study | 2012 | Change in the serum levels of biomarkers of cartilage metabolism and inflammation | 1 | 84 days |
| 62 | NCT00365209 | Phase II A Trial of Curcumin Among Patients with Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci) | 44 | ≥40-year-old patients with a >3 pack-year smoking history | 2011 | Change in prostaglandin E2 (PGE2) values found in rectal aberrant crypt foci (ACF) tissue | 2 | 30 days |
| 63 | NCT02494141 | Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD | 68 | 6–25-year-old patients with an ADPKD diagnosis and normal renal function | 2021 | Change in brachial artery flow-mediated dilation (FMD-BA) and aortic pulse-wave velocity (aPWV) | 4 | 12 months |
| 64 | NCT04378972 | Anti-inflammatory Effect of Curcumin, Homotaurine, Vitamin D3 on Human Vitreous in Patients with Diabetic Retinopathy | 25 | ≥18-year-old patients with diabetic retinopathy requiring vitrectomy | 2019 | Analyze human vitreous samples’ pro-inflammatory cytokines | NA | 7 days |
| 65 | NCT04972045 | Bioavailability of Curcumin Capsules in Healthy Adult Subjects | 12 | 18–55-year-old healthy subjects with a BMI of 18–28 kg/m2 | 2021 | Measure Peak Plasma Concentration, area under the curve, Tmax and bioavailability | 1 | 3 days |
| 66 | NCT01489592 | Effect of Curcumin on Iron Metabolism in Healthy Volunteer (CURHEP) | 18 | 18–35-year-old healthy adults with a BMI of 18–25 and no HFE mutation | 2012 | Maximal variation of the serum hepcidin level after the oral administration of curcumin | 2 | 48 h |
| 67 | NCT01964846 | Effect of Antioxidant Intake on Cardiovascular Risk | 22 | 45–70-year-old healthy patients with a stable weight | 2015 | Change in the blood levels of anti- and pro-inflammatory markers | NA | 2 weeks |
| 68 | NCT02100423 | Curcumin and Cholecalciferol in Treating Patients with Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 35 | ≥18-year-old patients with a CLL or SLL diagnosis and adequate organ function | 2018 | Overall response rate (biologic response rate + complete response [CR] + partial response [PR]) based on NCI-WG (for CLL) and the Cheson criteria (for SLL | 2 | 2 years |
| 69 | NCT03530436 | Comparison of Curcumin Bioavailability | 12 | 18–35-year-old healthy individuals | 2018 | Pharmacokinetics of curcuminoids (curcumin, demethoxycurcumin, bisdemethoxycurcumin) at different time frames | NA | 24 h |
| 70 | NCT02529982 | Curcumin Supplementation and Patients with Type 2 Diabetes | 44 | 44–65-year-old patients with type 2 Diabetes Mellitus with a BMI of 18.5–30 kg/m2 | 2016 | Fasting blood sugar, insulin, HbA1c, homeostatic model assessment of insulin resistance and change in pancreatic B-cell function | NA | 10 weeks |
| 71 | NCT03066791 | Turmeric and Curcumin on Sebum Production | 30 | 18–50-year-old healthy individuals | 2017 | Sebum production | NA | 8 weeks |
| 72 | NCT01514370 | Dietary Supplement of Curcumin in Subjects with Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a (CONTAIN) | 80 | 18–60-year-old patients with multiple sclerosis under the treatment of IFN beta-1a for 6–12 months | 2016 | Number of subjects with active (new or enlarging) T2 lesions, as assessed by magnetic resonance imaging (MRI) at Month 12 | 2 | 24 months |
| 73 | NCT00475683 | Curcumin for Prevention of Oral Mucositis in Children Chemotherapy | 8 | 5–30-year-old patients diagnosed with cancer who received doxorubicin containing chemotherapy | 2010 | Measured change of an objective measurement of oral mucositis | 3 | 6 weeks |
| 74 | NCT00164749 | A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer’s Disease | 36 | ≥50-year-old patients of Chinese ethnicity with a progressive decline in memory ≥6 months | 2006 | Measured change in the isoprostane level in plasma and the A-beta level in serum | 2 | 6 months |
| 75 | NCT02152475 | Photodynamic Therapy (PDT) for Oral Disinfection | 30 | 20–35-year-old healthy adults who do not perform any oral hygiene | 2013 | Microbiological analysis by the total number of colony-forming units | 1 | 2 h |
| 76 | NCT01831193 | Effect of Oral Supplementation with Curcumin (Turmeric) in Patients with Proteinuric Chronic Kidney Disease | 120 | 18–70-year-old patients diagnosed with proteinuric chronic kidney disease taking ARB or ACEi | 2014 | Change in proteinuria | 3 | 8 weeks |
| 77 | NCT02556632 | Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients with Non-inflammatory Breast Cancer (Curcumin-II) | 191 | ≥21-year-old patients diagnosed with non-inflammatory breast cancer or carcinoma in situ who are undergoing radiation therapy | 2016 | Measured mean Radiation Dermatitis Severity (RDS) score, incidence of moist sesquamation and change in the severity of skin reactions using RDS | 2 | 1 week post-radiation chemotherapy |
| 78 | NCT04465851 | Effect of Ferrous iROn and cUrcumin sTatus on Inflammatory and Neurotrophic markErs (Fe-ROUTINE) | 155 | 18–40-year-old healthy individuals | 2020 | To assess the influence of curcumin administration on ferrous iron supplementation-associated inflammation | NA | 42 days |
| 79 | NCT00192842 | Gemcitabine With Curcumin for Pancreatic Cancer | 17 | ≥18-year-old patients suffering from advanced or metastatic pancreatic adenocarcinoma with no prior therapy | 2010 | time to tumor progression | 2 | NA |
| 80 | NCT00099710 | Curcumin in Patients with Mild to Moderate Alzheimer’s Disease | 33 | ≥50-year-olds with a diagnosis of Alzheimer’s disease | 2007 | Measured safety and tolerability of curcumin | 2 | 12 months |
| 81 | NCT01712542 | Curcumin Bioavailability in Glioblastoma Patients | 15 | ≥18-year-old patients with glioblastoma | 2013 | Measured concentration of curcumin in glioblastoma | NA | At time of tumor resection |
| 82 | NCT01022632 | Effect of Curcumin as Nutraceutical in Patients of Depression | 60 | 18–65-year-old patients with a diagnosis of depression | 2010 | Measured response and mean change in the Hamilton Depression Rating Scale (HAM-D17) | NA | 6 weeks |
| 83 | NCT03144882 | Evaluation of Curcumin’s Effect on Inflammation in Hemodialysis Patients | 71 | ≥18-year-old clinically stable patients receiving hemodialysis | 2017 | Measured mean Interleukin-6 levels | NA | 1 year |
| 84 | NCT03141918 | Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV/AIDS | 20 | 18–70-year-old patients with HIV receiving antiretroviral therapy ≥6 months | 2017 | Measuring the oxidation of energetic substrates; evaluation at rest | NA | 10 days |
| 85 | NCT01740323 | Phase II Study of Curcumin vs. Placebo for Chemotherapy-Treated Breast Cancer Patients Undergoing Radiotherapy | 30 | ≥18-year-old female patients undergoing breast radiotherapy | 2018 | Measured change in NF-kB DNA binding, Plasma TNF-alpha, sTNFR2, IL-1ra, IL-6 and CRP | 2 | 6 weeks after the completion of radiotherapy |
| 86 | NCT04107987 | Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia | 148 | 18–75-year-old patients with impaired fasting glucose who are not on treatment | 2019 | Measured progression of dysglycemia | 3 | 3 months |
| 87 | NCT00027495 | Curcumin for the Prevention of Colon Cancer | NA | ≥18-year-old healthy individuals | 2007 | To determine the pharmacokinetics and measure the Maximum Tolerated Dose (MTD) | 1 | 72 h |
| 88 | NCT04723849 | Efficacy Evaluation of a Mixed Compound of Antioxidants in Terms of Endothelium Damage/Function in Pediatric Subjects with Obesity. (OBELIX) | 48 | 6–17-year-old patients with a BMI > 95% for their age based on the CDC standard | 2020 | To test the effects of a mixed compound including curcumin on endothelium in a cohort of pediatric subjects with obesity | NA | 6 months |
| 89 | NCT00768118 | A Nutritional Supplement Capsule Containing Curcumin, Green Tea Extract, Polygonum Cuspidatum Extract, and Soybean Extract in Healthy Participants | 11 | ≥18-year-old healthy individuals | 2008 | Measure the magnitude of change in the blood lymphocyte NF-kB level | NA | 15 days |
| 90 | NCT02017353 | Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma | 7 | ≥18-year-old female patients with endometrial carcinoma and no life-threatening metastases | 2016 | Measured change in the inflammatory markers in peripheral blood from the baseline | 2 | 21 days |
| 91 | NCT00792818 | The Efficacy and Safety of Curcuma Domestica Extracts and Ibuprofen in Knee Osteoarthritis | 367 | 50–75-year-old patients diagnosed with primary osteoarthritis | 2012 | Measured change in mean Western Ontario and McMaster Universities Osteoarthritis (WOMAC) pain subscale | 3 | 12 months |
| 92 | NCT03290417 | Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer | 37 | Patients diagnosed with prostate cancer who are on active surveillance | 2019 | Measured gene expression of very low and low-risk prostate cancer patients on active surveillance | NA | 12 months |
| 93 | NCT00525421 | A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus | 20 | ≥21-year-old patients diagnosed with lichen planus | 2009 | Measured percent change from the baseline to two weeks in the symptoms and signs of oral lichen planus | 2 | 2 weeks |
| 94 | NCT02337192 | Antimicrobial Photodynamic Therapy Applied in Orthodontic Patients. | 24 | 18–50-year-old healthy individuals with fixed orthodontic treatment | 2014 | Microbiological analysis by the total number of colony-forming units (CFU) | 1 | 1 h |
| 95 | NCT01288859 | Physiological Effects of New Polyphenol-enriched Foods in Humans | 10 | 18–45-year-old healthy individuals | 2011 | Measured serum polyphenol concentrations, urinary excretion of total polyphenols and the number of total fecal polyphenols | NA | 24 h |
| 96 | NCT01029327 | Effects of Curcumin on Postprandial Blood Glucose, and Insulin in Healthy Subjects | 15 | ≥18-year-old healthy individuals | 2009 | To study the effect of curcumin on the postprandial blood glucose and plasma concentrations of insulin | NA | NA |
| 97 | NCT02815475 | Turmeric Anti-Inflammatory and Cell-Damage Trial (TACT) | 90 | 18–80-year-old healthy individuals | 2016 | Measured change from baseline DNA methylation analyses and baseline oxidative stress determination | NA | 6 weeks |
| 98 | NCT03769857 | NEM® + BIOCURC® Versus Placebo in Exercise-induced Joint Pain, Stiffness, & Cartilage Turnover in Healthy Men & Women | 84 | 40–75-year-old healthy adults with no diagnosis of joint arthritis | 2019 | Measured exercise-induced cartilage turnover | NA | 2 weeks |
| 99 | NCT03621865 | A Comparative Pharmacokinetic Study to Evaluate the Ability of a New Formulation to Enhance Curcuminoids Bioavailability (TURBIO) | 30 | 18–45-year-old healthy individuals with a normal BMI and a stable weight | 2018 | Measured dose-normalized AUC of total curcuminoids plasmatic concentration | NA | 24 h |
| 100 | NCT03289832 | Effect of Orally Delivered Phytochemicals on Aging and Inflammation in the Skin | 25 | 18–70-year-old healthy individuals willing to avoid sun exposure and follow a diet | 2019 | Measured change in erythema 1, 2 and 3 Days after UV exposure | NA | 10 days |
| 101 | NCT03140657 | The Effects of Nanocurcumin on Treg Cells and Th17 Cells Responses in Ankylosing Spondylitis Patients | 24 | 23–46-year-old patients with a diagnosis of ankylosing spondylitis | 2018 | Assessments of ankylosing spondylitis signs and symptoms (BASDI) | 2 | 4 months |
| 102 | NCT03192059 | Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer (PRIMMO) | 43 | ≥18-year-old female patients with endometrial, cervical or uterine malignancy refractory to treatment | 2021 | Measured efficacy (objective response rate) at week 26 according to the immune-related response criteria (irRC) | 2 | 156 weeks |
| 103 | NCT03530787 | Cosmetic Effects of Topical Acetyl Zingerone | 31 | 30–60-year-old healthy individuals | 2018 | Measured change in wrinkle appearance and skin pigmentation | NA | 8 weeks |
| 104 | NCT03493997 | Multicentre International STudy for the Prevention with Ialuril® of Radio-induced Cystitis (MISTIC) | 100 | ≥18-year-old male patients who planned to receive primary therapy for prostate cancer | 2018 | Measured rate of patients who stopped treatment with intravesical or oral ialuril due to intolerance or adverse events | 2 | 12 months |
| 105 | NCT04849182 | Vertistop® D and Vertistop® L in Preventing Recurrence of High-recurrence BPPV | 128 | 18–85-year-old patients with benign paroxysmal positional vertigo (BPPV) | 2020 | Measured number of BPPV recurrences in patients supplemented with Vertistop D | NA | 6 months |
| 106 | NCT02099890 | The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury | 20 | ≥18-year-old patients with a spinal cord injury | 2015 | Measured change from the baseline in the nerve conduction velocity of somatic nerves at 3 and 6 months | 3 | 6 months |
| 107 | NCT03483376 | aPDT for the Remediation of Dental Black Stain | 30 | ≥12-year-old patients with a dental black stain in at least two teeth | 2020 | Area and depth of color of the black stain | NA | 6 months |
| 108 | NCT00235625 | Curcuminoids for the Treatment of Chronic Psoriasis Vulgaris | 12 | 18–75-year-old patients with chronic plaque-type psoriasis | 2007 | Physicians Global Assessment (PGA) of change | 2 | 16 weeks |
| 109 | NCT04382040 | A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19 | 50 | ≥18-year-old patients with a diagnosis of SARS-CoV-2 infection who are hospitalized and are in stable condition | 2020 | Time to clinical improvement, defined as a national Early Warning Score 2 (NEWS2) of ≤ 2, maintained for 24 h, and measurement of adverse events | 2 | 2 weeks |
| 110 | NCT03150966 | The Immunomodulatory Effects of Oral Nanocurcumin in Multiple Sclerosis Patients | 41 | 18–65-year-old patients who are diagnosed with multiple sclerosis | 2017 | Measurement of the Expanded Disability Status Scale (EDSS) | 2 | 6 months |
| 111 | NCT02442453 | Effect of Scaling and Root Planing Along with Topical Application of Commercially Available Curcuma Longa Gel on Superoxide Dismutase and Malondialdehyde Levels in Saliva of Chronic Periodontitis Patients | 100 | 30–55-year-old healthy individuals with chronic generalized periodontitis | 2014 | Measurement of the superoxide dismutase antioxidant enzyme levels in the saliva of chronic periodontitis subjects | 4 | 1 month |
| 112 | NCT02909621 | Evaluation of FLEXOFYTOL® Versus PLACEBO (COPRA) | 150 | 45–80-year-old patients with knee osteoarthritis | 2017 | Measuring the variation in the serum levels of the sColl2-1 biomarker between T0 and T3 by specific immunoassays and the variation in the global assessment of disease activity by the patient using a visual analogue scale (VAS) | NA | 6 months |
| 113 | NCT04439981 | Curcuma Extract Beneficial for Muscle Damage | 20 | 14–18-year-old healthy male individuals | 2019 | Change in lactic acid, Hb, IL-6 and creatinine kinase | NA | 21 days |
| 114 | NCT02251678 | Evaluate the Effect of Elimune Capsules | 21 | ≥18-year-old patients with plaque psoriasis with or without arthritis | 2015 | Individual subject serum levels of biomarkers (CRP, TNFa, IL-6, IL-12) | 1 | 28 days |
| 115 | NCT04633551 | Vascular Inflammation and Anti-inflammatory Supplements After Adverse Pregnancy Outcomes (VIA) | 8 | 18–45-year-old female patients who had a singleton pregnancy of < 3 years complicated by an adverse pregnancy outcome (APO) | 2021 | Measurement of blood pressure, arterial stiffness, augmentation index and endothelial function | NA | 1 month |
| 116 | NCT02834078 | Effect of BGG on Glucose Metabolism and Other Markers of Metabolic Syndrome (Glucogold) | 126 | 20–60-year-old patients with a BMI ≥ 25 suffering from pre-diabetes or early diagnosed diabetes | 2016 | Measured change in the oral disposition index and HbA1c | NA | 84 days |
| 117 | NCT04149639 | A Study Investigating the Effectiveness of a LifeSeasons NeuroQ Supplement with Lifestyle Changes to Improve Cognitive Function in Healthy Adults Who Have One or More Risk Factors for Cognitive Decline | 40 | ≥45-year-old patients with risk factors for cognitive decline | 2020 | Measured change in cognition as assessed by the change in the Neurocognitive Index (NCI) score from the CNS-Vital Signs (CNS-VS) panel | NA | 135 days |
| 118 | NCT01716637 | Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer’s Disease | 12 | 60–85-year-old patients with a diagnosis of Alzheimer’s disease | 2016 | Difference in the effects of the treatment for 6 weeks with etanercept + nutritional supplements versus nutritional supplements alone on the Mini-Mental Status Examination (MMSE) score | 1 | 16 weeks |
| 119 | NCT01752868 | Can Fish Oil and Phytochemical Supplements Mimic Anti-Aging Effects of Calorie Restriction? | 56 | 40–60-year-old patients with a BMI of 21–30 kg/m2 who are sedentary to moderately active | 2012 | Carotid-femoral pulse wave velocity | NA | 6 months |
| 120 | NCT00799630 | Effects of Nutraperf Consumption in Runners | 14 | 18–46-year-old healthy male distance runners | 2008 | Measurement of different metabolic parameters (heart rate, oxygen consumption, respiratory quotient, ventilation, glycemia, lactatemia) on central and peripheral fatigue and on cognitive parameters | NA | NA |
| 121 | NCT04765527 | Turmeric and Exercise-Induced Muscle Damage and Oxinflammation | 53 | 18–50-year-old healthy individuals who are willing to exercise | 2021 | Measuring a change in the serum concentration of creatine kinase | NA | 4 days |
| 122 | NCT02413099 | The Efficacy and Safety of New Herbal Formula (KBMSI-2) in the Treatment of Erectile Dysfunction | 44 | 18–40-year-old male patients with a history of erectile dysfunction | 2013 | Measuring a change in the EF domain scores of the IIEF questionnaire from the baseline | 4 | 8 weeks |
| 123 | NCT01906840 | Role of Turmeric on Oxidative Modulation in ESRD Patients | 48 | ≥18-year-old patients who undergo regular dialysis | 2012 | Measuring the effects of turmerics on oxidative stress markers | 2 | 8 weeks |
| 124 | NCT01646047 | Diabetes Visual Function Supplement Study (DiVFuSS) | 70 | ≥18-year-old patients with a ≥5-year history of diabetes mellitus | 2014 | Measuring changes in visual function | NA | 6 months |
| 125 | NCT02369536 | Efficacy of a Natural Components Mixture in the Treatment of non-Alcoholic Fatty Liver Disease (NAFLD) (NUTRAFAST) | 126 | 18–80-year-old patients with non-alcoholic fatty liver disease (NAFLD) | 2016 | Hematic levels of hepatic enzymes AST, ALT and GGT | NA | 3 months |
| 126 | NCT02088307 | Study of the Cardiovascular Vitamin, CardioLife | 21 | 18–90-year-old patients with cardiovascular disease | 2016 | Change in blood pressure | NA | 6 months |
| 127 | NCT05089318 | Evaluation of Flexofytol® PLUS in Hand Osteoarthritis. | 239 | ≥45-year-old patients with hand arthritis and a regular use of analgesia | 2021 | Pain using a Visual Analog Scale (VAS) | NA | 84 days |
| 128 | NCT03482401 | Disposition of Dietary Polyphenols and Methylxanthines in Mammary Tissues from Breast Cancer Patients (POLYSEN) | 40 | ≥18-year-old patients diagnosed with breast cancer | 2019 | Quantification of dietary polyphenols and methylxanthines in breast tissues | NA | 24 months |
| 129 | NCT04890704 | Curcuminoids and Contrast-induced Acute Kidney Injury | 96 | 18–80-year-old patients undergoing elective CAG with a stable eGFR of 15–60 mL/min/1.72 m2 | 2019 | The incidence of CI-AKI development between the addition of curcuminoids to the standard protocol and the standard protocol alone in patients who underwent CAG | 1 | 48 h |
| 130 | NCT00219882 | Safety Study of Orally Administered Curcuminoids in Adult Subjects with Cystic Fibrosis (SEER) | 11 | 18–40-year-old patients who suffer from cystic fibrosis (homozygous for the ΔF508 CFTR genotype) | 2006 | Safety and tolerability of 14 days of treatment with orally administered curcuminoids, as assessed by adverse events, laboratory parameters and spirometry | 1 | 14 days |
| 131 | NCT04844658 | COVID-19, Hospitalized, PatIents, Nasafytol | 51 | ≥18-year-old patients with a recent hospitalization due to SARS-CoV-2 | 2021 | Improvement of the patient’s clinical condition based on the WHO ordinal outcomes score, the duration of hospitalization, mortality, fever, oxygen therapy, adverse events and several blood parameters | NA | 14 days |
| 132 | NCT03065504 | Turmeric and Turmeric-containing Tablets and Sebum Production | 30 | 18–50-year-old healthy individuals | 2017 | Change in facial sebum production | NA | 4 weeks |
| 133 | NCT04281758 | Comparison of Plasma Caffeine Concentration After Oral Consumption of Caffeinated Beverages with Varied Bioactive Compounds in Healthy Volunteers | 16 | 18–55-year-old healthy individuals willing to avoid caffeine and alcohol for a period of time | 2020 | Incremental area-under-the-concentration-curve (iAUC) | 1 | 210 min |
| 134 | NCT04258501 | Exploratory Study of Efficacy on Selected Natural Extracts Reducing Post Prandial Blood Glucose Response | 72 | 20–50-year-old healthy individuals with a normal BMI | 2012 | Change in post-prandial blood glucose | NA | 2 h |